β-blockers and breast cancer survival by molecular subtypes: a population-based cohort study and meta-analysis
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background: The association between use of β-blockers and breast cancer (BC) prognosis has been investigated in several observational studies, with conflicting results. We performed a nationwide cohort study and a meta-analysis to investigate the association, and assess if it varied between molecular subtypes of BC. Methods: We identified women aged ≥50 years with BC diagnosed between 2004 and 2018 in Norway. We used Cox regression models to estimate the association between β-blocker use at diagnosis and BC-specific survival, overall and by molecular subtype. We performed a meta-analysis of observational studies that reported molecular subtype-specific estimates of this association. Results: We included 30,060 women, of which 4461 (15%) used β-blockers. After a median follow-up of 5.1 years, 2826 (9%) died of BC. Overall, β-blocker use was not associated with BC-specific survival (hazard ratio [HR] = 1.07; 95% confidence interval [CI]: 0.97–1.19). We found an association only in triple-negative BC (TNBC) patients (HR = 0.66; 95% CI: 0.47–0.91). This was confirmed in the meta-analysis: β-blocker use was associated with progression/recurrence-free (HR = 0.58; 95% CI: 0.38–0.89) and BC-specific survival (HR = 0.74; 95% CI: 0.55–1.00) in TNBC patients only. Conclusion: In our cohort of BC patients and in the meta-analysis, β-blocker use was associated with prolonged BC-specific survival only in TNBC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma
Thaker, P. H., Han, L. Y., Kamat, A. A., Arevalo, J. M., Takahashi, R., Lu, C., Jennings, N. B., Armaiz-Pena, G., Bankson, J. A., Ravoori, M., et al. (2006) · Nature Medicine · doi:10.1038/nm1447 · Cited by 1,320 · cited 1×
“β-adrenergic signalling is involved in various processes during tumour progression, including suppression of antitumor immunity [5, 6], vasculature remodelling [7, 8], and tumour cell dissemination [9, 10].”
BackgroundThe sympathetic nervous system induces a metastatic switch in primary breast cancer
Sloan, E. K., Priceman, S. J., Cox, B. F., Yu, S., Pimentel, M. A., Tangkanangnukul, V., Arevalo, J. M. G., Morizono, K., Karanikolas, B. D. W., Wu, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0522 · Cited by 930
Self-citationLarsen, I. K., Småstuen, M., Johannesen, T. B., Langmark, F., Parkin, D. M., Bray, F., & Møller, B. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.037 · Cited by 848
Perioperative events influence cancer recurrence risk after surgery
Hiller, J. G., Perry, N. J., Poulogiannis, G., Riedel, B., & Sloan, E. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.194 · Cited by 556 · cited 1×
“The time period surrounding cancer diagnosis and treatment is stressful for the patient [56, 59].”
BackgroundSelf-citationChronic stress in mice remodels lymph vasculature to promote tumour cell dissemination
Le, C. P., Nowell, C. J., Kim-Fuchs, C., Botteri, E., Hiller, J. G., Ismail, H., Pimentel, M. A., Chai, M. G., Karnezis, T., Rotmensz, N., et al. (2016) · Nature Communications · doi:10.1038/ncomms10634 · Cited by 354
Self-citationBucsek, M. J., Qiao, G., MacDonald, C. R., Giridharan, T., Evans, L., Niedzwecki, B., Liu, H., Kokolus, K. M., Eng, J. W.-L., Messmer, M. N., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0546 · Cited by 294
Cited by
Pellegata, N. S., Berriel Diaz, M., Rohm, M., & Herzig, S. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10058-y · Cited by 33
Impact of the ONCOBIOME network in cancer microbiome research
Zitvogel, L., Derosa, L., Routy, B., Loibl, S., Heinzerling, L., de Vries, I. J. M., Engstrand, L., ONCOBIOME Network, Silva, C. A. C., Barbieri, D., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03608-8 · Cited by 23
Al-Hussaini, I., Nakajima An, D., Lee, A. J., Bi, S., & Mitchell, C. S. (2022) · 2022 IEEE International Conference on Big Data (Big Data) · doi:10.1109/bigdata55660.2022.10020807 · Cited by 10
“566 35725814 [55] β-blockers and breast cancer survival by molecular subtypes: a population-based cohort study and meta-analysis.”
Background
Metadata
- Authors
- Løfling, L. L., Støer, N. C., Sloan, E. K., Chang, A., Gandini, S., Ursin, G., & Botteri, E.
- Venue
- British Journal of Cancer
- Published
- 2022-06-20
- Volume
- 127
- Issue
- 6
- Pages
- 1086-1096
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W4283164974
- Cited by
- 59
- References
- 6
- FWCI
- 3.68
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: β-blockers and breast cancer survival by molecular subtypes: a population-based cohort study and meta-analysis. https://app.cochat.ai/papers/10.1038/s41416-022-01891-7
- The paper
- Løfling, L. L., Støer, N. C., Sloan, E. K., Chang, A., Gandini, S., Ursin, G., & Botteri, E. (2022). β-blockers and breast cancer survival by molecular subtypes: a population-based cohort study and meta-analysis. British Journal of Cancer. https://doi.org/10.1038/s41416-022-01891-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.